

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - protein search, using frame_plus_r2p model

Run on: August 17, 2004, 15:13:02 ; Search time 0.001 Seconds
(without alignments)
409.920 Million cell updates/sec

Title: us-09-270-437d-5
Perfect score: 3110
Sequence: 1 agggagcgtgcgcacgcgc.....atttccttcagggttttaaaa 1708

Scoring table: BLOSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 6 seqs, 120 residues

Total number of hits satisfying chosen parameters: 12

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 6 summaries

Command line parameters:

-MODEL=frame+hzp.model -DEV=soft -Q=us-09-270-437d-5 -DB=* Geneseqp*
-SUFFIX=ptc -OUT=align5 -MINMATCH=0.1 -LOPCU=0 -LOPEXT=0 -UNITS=bits
-START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cgi -LIST=6 -DOCALIGN=200
-THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=6 -MODE=LOCAL -OUTFMT=ptc
-NORM=ext -HEADSIZE=500 -MINLEN=0 -MAXLEN=200000000 -NCPU=6 -NO XLPXY
-NEG SCORES=0 -LONGLOG -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6 -FGAPEXT=7
-YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : *.geneseqp*:

1: /home/sdavid/sdavid-tmp/aug04/canella437/abb75042.geneseqp2002s*
2: /home/sdavid/sdavid-tmp/aug04/canella437/abb75041.geneseqp2002s*
3: /home/sdavid/sdavid-tmp/aug04/canella437/abp61961.geneseqp2002s*
4: /home/sdavid/sdavid-tmp/aug04/canella437/abp61962.geneseqp2002s*
5: /home/sdavid/sdavid-tmp/aug04/canella437/ada28504.geneseqp2003bs*
6: /home/sdavid/sdavid-tmp/aug04/canella437/ada28505.geneseqp2003bs*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	101	3.2	20	1 ABB75042	Human lung tumour
2	101	3.2	20	4 ABP61962	Human lung cancer
3	101	3.2	20	6 ADA28505	Human lung tumour
4	96	3.1	20	2 ABB75041	Human lung tumour
5	96	3.1	20	3 ABP61961	Human lung cancer
6	96	3.1	20	5 ADA28504	Human lung tumour

ALIGNMENTS

RESULT 1
ID ABB75042
ID ABB75042 standard; peptide; 20 AA.
XX
AC ABB75042;

XX 01-MAY-2002 (first entry)
DT Human lung tumour L523S peptide SEQ ID NO:415.
DE
XX Human lung tumour; lung cancer; cytostatic; immunostimulant; vaccine;
XX immune response.
KW
XX Homo sapiens.
OS
XX WO200200174-A2.
FN
XX 03-JAN-2002.
PD
XX 28-JUN-2001; 2001WO-US021065.
PF
XX 28-JUN-2000; 2000US-00606421.
PR 02-AUG-2000; 2000US-00630940.
PR 21-AUG-2000; 2000US-00643597.
PR 15-SEP-2000; 2000US-00662786.
PR 09-OCT-2000; 2000US-00685696.
PR 12-DEC-2000; 2000US-00735705.
PR 07-MAY-2001; 2001US-00850716.
XX
XX (CORI-) CORIXA CORP.
XX Wang T, Wang A, Skeiky YAW, Li SX, Kalos MD, Henderson RA;
PI McNeill PD, Fanger N, Retter MW, Marnerakis M, Fanger GR;
PI Vedvick TS, Carter D, Watanabe Y, Peckham DW;
XX
XX WPI; 2002-090513/12.
DR
XX Polynucleotides encoding lung tumor polypeptides, useful for treating
PT lung cancer or stimulating an immune response.
XX
XX Claim 2; Page 351; 374pp; English.
PS
XX The present invention describes human lung tumour proteins. Human lung
CC tumour proteins and polynucleotides have cytostatic and immunostimulant
CC activities, and can be used in vaccine production. Compositions
CC comprising the lung tumour proteins, polynucleotides, antibodies, fusion
CC proteins, T cell populations, or antigen presenting cells that express
CC the lung tumour proteins are useful for treating lung cancer or
CC stimulating an immune response. ABI48959 to ABL49300 and ABB74946 to
CC ABB75070 represent sequences used in the exemplification of the present
CC invention
XX
XX Sequence 20 AA;
SQ

Alignment Scores:
Pred. No.: 1.61 Length: 20
Score: 101.00 Matches: 20
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 3.25% Indels: 0
DB: Gaps: 0

us-09-270-437d-5 (1-1708) x ABB75042 (1-20)

Cy 293 AACATCAAAACAGACCCAGTCCAGATGACGTGCTAGTAGGAGGACCGAGGTGCA 352
Db 1 AsnIleThrLysGlnThrGlnSerLysIleAspValHisArgLysGluAsnAlaGlyAla 20

RESULT 2
ID ABP61962
ID ABP61962 standard; peptide; 20 AA.
XX
XX ABP61962;
XX
XX 07-OCT-2002 (first entry)
DT
XX Human lung cancer associated peptide sequence SEQ ID NO:415.
DE
XX

KW Human; lung cancer; lung tumour; cytostatic; gene therapy; vaccine.
 XX Homo sapiens.
 OS WO200247534-A2.
 PN 20-JUN-2002.
 PD 30-NOV-2001; 2001WO-US047576.
 PF 12-DEC-2000; 2000US-00735705.
 XX 07-MAY-2001; 2001US-00850716.
 PR 28-JUN-2001; 2001US-00897778.
 XX (CORI-) CORIXA CORP.
 PA Wang T, Wang A, Skeiky YAW, Li SX, Kalos MD, Henderson RA;
 PI McNeill PD, Fanger N, Retter MW, Durham M, Fanger GR, Vedvick TS;
 PI Carter D, Watanabe Y, Peckham DW, Cai F, Foy TM;
 XX WPI; 2002-583465/62.
 XX Novel lung carcinoma polynucleotide sequences and polypeptides encoded by
 PT the polynucleotides, useful in pharmaceutical compositions such as
 PT vaccines and as markers to indicate the presence of lung cancer.
 XX Claim 9; Page 358; 381pp; English.
 XX The present invention describes isolated human lung carcinoma
 CC polynucleotides (I) and polypeptides (II). (I) and (II) have cytostatic
 CC activity, and can be used in gene therapy and in vaccines. Compositions
 CC comprising (I) or (II) can be used for stimulating an immune response in
 CC a patient and for treating lung cancer in a patient. Oligonucleotides of
 CC (I) can be used for detecting the presence of a cancer in a patient, by
 CC obtaining a biological sample from the patient, contacting the biological
 CC sample with the oligonucleotide, detecting in the sample, an amount of
 CC polynucleotide that hybridises to the oligonucleotide and comparing the
 CC amount of polynucleotide that hybridises to the oligonucleotide to a
 CC predetermined cut-off value, and determining the presence of a cancer in
 CC the patient. (I) and (II) are useful in pharmaceutical compositions, e.g.
 CC vaccines. (I) is useful as a marker to indicate the presence or absence
 CC of a cancer such as lung cancer. ABQ92145 to ABQ92486 and ABP61866 to
 CC ABP61992 represent sequences used in the exemplification of the present
 CC invention
 XX SQ Sequence 20 AA;
 Alignment Scores:
 Pred. No.: 1.61 Length: 20
 Score: 101.00 Matches: 20
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 3.25% Indels: 0
 DB: 4 Gaps: 0
 us-09-270-437d-5 (1-1708) x ABP61962 (1-20)
 QY 293 AACATCACAACAGACCCAGTCCAGATAGACGTGCATAGGAGAGAACGCGGTGCA 352
 Db 1 AsnIleThrLysGlnThrGlnSerLysIleAspValHisArgLysGluAsnAlaGlyAla 20
 RESULT 3
 ADA28505
 ID ADA28505 standard; peptide; 20 AA.
 XX ADA28505;
 AC 20-NOV-2003 (first entry)
 DT Human lung tumour associated protein L523S peptide #20.
 DE cancer; lung cancer; gene therapy; vaccine; human;
 XX lung squamous cell carcinoma.
 KW

XX Homo sapiens.
 OS US2003064947-A1.
 PN 03-APR-2003.
 PD 30-NOV-2001; 2001US-00007700.
 PF 18-MAR-1998; 98US-00040802.
 XX 27-JUL-1998; 98US-00123912.
 PR 22-DEC-1998; 98US-00221107.
 PR 02-APR-1999; 98US-00285479.
 PR 17-DEC-1999; 99US-00456396.
 PR 30-DEC-1999; 99US-00476496.
 PR 10-JAN-2000; 2000US-00480884.
 PR 22-FEB-2000; 2000US-00510376.
 PR 04-APR-2000; 2000US-00542615.
 PR 28-JUN-2000; 2000US-00606421.
 PR 02-AUG-2000; 2000US-00630940.
 PR 21-AUG-2000; 2000US-00643597.
 PR 15-SEP-2000; 2000US-00662786.
 PR 09-OCT-2000; 2000US-00685696.
 PR 12-DEC-2000; 2000US-00735705.
 PR 07-MAY-2001; 2001US-00850716.
 PR 28-JUN-2001; 2001US-00897778.
 XX (CORI-) CORIXA CORP.
 PA Wang T, Wang A, Skeiky YAW, Li SX, Kalos MD, Henderson RA;
 PI McNeill PD, Fanger N, Retter MW, Durham M, Fanger GR, Vedvick TS;
 PI Carter D, Watanabe Y, Peckham DW, Cai F, Foy TM;
 XX WPI; 2003-540798/51.
 XX New isolated polynucleotides and polypeptides useful for diagnosing,
 PT preventing and/or treating cancer, particularly lung cancer.
 PT Claim 9; Page 270-271; 296pp; English.
 PS The invention describes isolated polynucleotides and polypeptides useful
 CC for diagnosing, preventing and/or treating cancer, particularly lung
 CC cancer. A new isolated polynucleotide comprises: any of the 22 fully
 CC defined nucleotide sequences (e.g. 1012, 900 or 2773 bp) given in the
 CC specification; complements of the nucleotide sequences cited above; at
 CC least 10 contiguous residues of the nucleotide sequences cited above; a
 CC sequence that hybridise to any of the nucleotide sequences under highly
 CC stringent conditions; a sequence that is at least 75 or 90% identical to
 CC the above nucleotide sequences; or degenerate variants of the above
 CC nucleotide sequences. The composition and methods are useful in
 CC diagnosing, preventing and/or treating cancer, particularly lung cancer,
 CC in gene therapy and in vaccines. This is the amino acid sequence of a
 CC human lung tumour associated protein L523S peptide.
 XX SQ Sequence 20 AA;
 Alignment Scores:
 Pred. No.: 1.61 Length: 20
 Score: 101.00 Matches: 20
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 3.25% Indels: 0
 DB: 6 Gaps: 0
 us-09-270-437d-5 (1-1708) x ADA28505 (1-20)
 QY 293 AACATCACAACAGACCCAGTCCAGATAGACGTGCATAGGAGAGAACGCGGTGCA 352
 Db 1 AsnIleThrLysGlnThrGlnSerLysIleAspValHisArgLysGluAsnAlaGlyAla 20
 RESULT 4
 ABB75041
 ID ABB75041 standard; peptide; 20 AA.

*good CRF, no separate list
in your sig
database
CR reading
database*

XX ABB75041;
XX AC
XX DT
DT 01-MAY-2002 (first entry)
XX
DE Human lung tumour L523S peptide SEQ ID NO:414.
XX
KW Human; lung tumour; lung cancer; cytostatic; immunostimulant; vaccine;
KW immune response.
XX
OS Homo sapiens.
XX
PN WO200200174-A2.
XX
PD 03-JAN-2002.
XX
PF 28-JUN-2001; 2001WO-US201065.
XX
PR 28-JUN-2000; 2000US-00606421.
PR 02-AUG-2000; 2000US-00630940.
PR 21-AUG-2000; 2000US-00843597.
PR 15-SEP-2000; 2000US-00662786.
PR 09-OCT-2000; 2000US-00685696.
PR 12-DEC-2000; 2000US-00735705.
PR 07-MAY-2001; 2001US-00850716.
XX
PA (CORI-) CORIXA CORP.
XX
PI Wang T, Wang A, Skeiky YAW, Li SX, Kalos MD, Henderson PA;
PI McNeill PD, Fanger N, Retter MW, Marnierakis M, Fanger GR;
PI Vedvick TS, Carter D, Watanabe Y, Peckham DW;
XX
DR WPI; 2002-090513/12.
XX
PT Polynucleotides encoding lung tumor polypeptides, useful for treating
PT lung cancer or stimulating an immune response.
XX
PS Claim 2; Page 351; 374pp; English.
XX
CC The present invention describes human lung tumour proteins. Human lung
CC tumour proteins and polynucleotides have cytostatic and immunostimulant
CC activities, and can be used in vaccine production. Compositions
CC comprising the lung tumour proteins, polynucleotides, antibodies, fusion
CC proteins, T cell populations, or antigen presenting cells that express
CC the lung tumour proteins are useful for treating lung cancer or
CC stimulating an immune response. ABL48959 to ABL49300 and ABB74946 to
CC ASB75070 represent sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 20 AA;

Alignment Scores:
Pred. No.: 1.87 Length: 20
Score: 96.00 Matches: 20
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 3.09% Indels: 0
DB: 2 Gaps: 0

us-09-270-437d-5 (1-1708) x ABB75041 (1-20)

Oy 263 ATTATTGGCAGAGCGGCGCACATCCGCACATCAACAACAGCCCAGTCCAAGATA 322
Db 1 IleileGlynsGlucGlyAlaThrleargasnilerhrysGlnnrGinSerLyslie 20

RESULT 5
ABP61961
ID ABP61961 standard; peptide; 20 AA.
XX AC ABP61961;
XX DT 07-OCT-2002 (first entry)
XX

Human lung cancer associated peptide sequence SEQ ID NO:414.

Human; lung cancer; lung tumour; cytostatic; gene therapy; vaccine.

Homo sapiens.

WO200247534-A2.

20-JUN-2002.

30-NOV-2001; 2001WO-US047576.

12-DEC-2000; 2003US-00735705.

07-MAY-2001; 2001US-00850716.

28-JUN-2001; 2001US-00897778.

(CORI-) CORIXA CORP.

Wang T, Wang A, Skeiky YAW, Li SX, Kalos WD, Henderson RA; McNeill PD, Fanger N, Retter MW, Durham M, Fanger GR, Vedvick TS; Carter D, Watanabe Y, Peckham DW, Cai F, Foy TM;

WPI; 2002-583465/62.

Novel lung carcinoma polynucleotide sequences and polypeptides encoded by the polynucleotides, useful in pharmaceutical compositions such as vaccines and as markers to indicate the presence of lung cancer.

Claim 9; Page 358; 381pp; English.

The present invention describes isolated human lung carcinoma polynucleotides (I) and polypeptides (II). (I) and (II) have cytostatic activity, and can be used in gene therapy and in vaccines. Compositions comprising (I) or (II) can be used for stimulating an immune response in a patient and for treating lung cancer in a patient. Oligonucleotides of (I) can be used for detecting the presence of a cancer in a patient, by obtaining a biological sample from the patient, contacting the biological sample with the oligonucleotide, detecting in the sample, an amount of polynucleotide that hybridises to the oligonucleotide and comparing the amount of polynucleotide that hybridises to the oligonucleotide to a predetermined cut-off value, and determining the presence of a cancer in the patient. (I) and (II) are useful in pharmaceutical compositions, e.g. vaccines. (I) is useful as a marker to indicate the presence or absence of a cancer such as lung cancer. ABQ92145 to ABQ92486, and ABP61966 to ABP61992 represent sequences used in the exemplification of the present invention

Sequence 20 AA;

Alignment Scores:

Pred. No.:	1.87	Length:	20
Score:	96.00	Matches:	20
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	3.09%	Indels:	0
DB:	3	Gaps:	0

us-09-270-437d-5 (1-1708) x ABP61961 (1-20)

QY 263 ATTATTGGCAAGGAGGGGCCACCATCCGCAACATCACAAAACAGACCAGTCCAGATA 3322

Db 1 IleIleGlyLysGluGlyAlaThrIleArgAsnIleThrLysGlnThrGlnSerLysIle 20

RESULT 6

ADA28504

ID ADA28504 standard; peptide; 20 AA.

XX AC

XX ADA28504;

XX ADA28504;

DT 20-NOV-2003 (first entry)

XX DE

XX Human lung tumour associated protein L523S peptide #19.

XX

KW cancer; lung cancer; gene therapy; vaccine; human;
XX lung squamous cell carcinoma.

OS Homo sapiens.

XX US2003064947-A1.

XX 03-APR-2003.

XX 30-NOV-2001; 2001US-00007700.

XX 18-MAR-1998; 98US-00040802.

XX 27-JUL-1998; 98US-00123912.

XX 22-DEC-1998; 98US-00221107.

XX 02-APR-1999; 99US-00285479.

XX 17-DEC-1999; 99US-00486396.

XX 30-DEC-1999; 99US-00476496.

XX 10-JAN-2000; 2000US-00480884.

XX 22-FEB-2000; 2000US-00510376.

XX 04-APR-2000; 2000US-00542615.

XX 28-JUN-2000; 2000US-00606421.

XX 02-AUG-2000; 2000US-00630940.

XX 21-AUG-2000; 2000US-00643597.

XX 15-SEP-2000; 2000US-00662786.

XX 09-OCT-2000; 2000US-00685696.

XX 12-DEC-2000; 2000US-00735705.

XX 07-MAY-2001; 2001US-00850716.

XX 28-JUN-2001; 2001US-00897778.

XX (CORI-) CORIXA CORP.

XX Wang T, Wang A, Skeiky YAM, Li SX, Kalos MD, Henderson RA;

XX McNeill PD, Fanger N, Retter MW, Durham M, Fanger GR, Vedvick TS;

XX Carter D, Watanabe Y, Peckham DW, Cai F, Foy TM;

XX WPI; 2003-540798/51.

XX New isolated polynucleotides and polypeptides useful for diagnosing,

XX preventing and/or treating cancer, particularly lung cancer.

XX Claim 9; Page 270; 296pp; English.

XX The invention describes isolated polynucleotides and polypeptides useful

XX for diagnosing, preventing and/or treating cancer, particularly lung

XX cancer. A new isolated polynucleotide comprises: any of the 22 fully

XX defined nucleotide sequences (e.g. 1012, 900 or 2773 bp) given in the

XX specification; complements of the nucleotide sequences cited above; at

XX least 10 contiguous residues of the nucleotide sequences cited above; a

XX sequence that hybridise to any of the nucleotide sequences under highly

XX stringent conditions; a sequence that is at least 75 or 90% identical to

XX the above nucleotide sequences; or degenerate variants of the above

Search completed: August 17, 2004, 15:13:03
Job time : 1 secs

Alignment Scores:
Pred. No.: 1.87 Length: 20
Score: 96.00 Matches: 20
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 3.09% Indels: 0
DB: Gaps: 0

us-09-270-437d-5 (1-1708) x ADA28504 (1-20)

QY 263 ATTATTGCAAGGAGGGGGCCACCATCCGCAACATCAAAACAGACCAGTCCAGATA 322

Db 1 lleileGlyLysGluGlyAlaThrileArgAsnileThrLysGlnThrGlnSerLysile 20